Lisinopril And Hydrochlorothiazide Tablet
FDA Label NDC 51655-414

22 label sections · Submitted to the FDA by Northwind Health Company, Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Northwind Health Company, Llc for the product Lisinopril And Hydrochlorothiazide (NDC 51655-414). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding description, clinical pharmacology, indications and usage, contraindications, warnings, general, aortic stenosis/hypertrophic cardiomyopathy:, impaired renal function:, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.